Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study
To deal with the COVID-19 pandemic, a mass vaccination campaign was started in European countries on 27 December 2020. The first vaccine available to immunize healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine. While many studies have shown a high antibody response after the second vac...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/3/417 |
| _version_ | 1797441186609233920 |
|---|---|
| author | Francesco Paolo Bianchi Pasquale Stefanizzi Cinzia Annatea Germinario Giovanni Migliore Luigi Vimercati Andrea Martinelli Annamaria Lobifaro Giusy Diella Angela Maria Vittoria Larocca Control Room Working Group Silvio Tafuri |
| author_facet | Francesco Paolo Bianchi Pasquale Stefanizzi Cinzia Annatea Germinario Giovanni Migliore Luigi Vimercati Andrea Martinelli Annamaria Lobifaro Giusy Diella Angela Maria Vittoria Larocca Control Room Working Group Silvio Tafuri |
| author_sort | Francesco Paolo Bianchi |
| collection | DOAJ |
| description | To deal with the COVID-19 pandemic, a mass vaccination campaign was started in European countries on 27 December 2020. The first vaccine available to immunize healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine. While many studies have shown a high antibody response after the second vaccine dose, antibody persistence over the medium-to-long term has yet to be evaluated. The medium-to-long-term persistence of anti-SARS-CoV-2 antibodies was determined in a sample of fully vaccinated HCWs at Bari Policlinico General Hospital, Italy. This is a observational cohort study. HCWs who completed the immunization basal cycle were screened for anti-SARS-CoV-2 IgG on days 15, 30, 60, 90, and 120 after the second vaccine dose. At each time point, >99% of the screened HCWs were seroprotected. While the geometric mean titer initially declined over time, by 60 days the titer had stabilized. Older subjects seem to lose IgG faster than younger ones. The immunogenicity conferred by the vaccine provides further evidence that it is an essential weapon in efforts to bring the COVID-19 pandemic under control. Accordingly, strict measures should be implemented, ranging from the mandatory vaccination of HCWs to strong incentives aimed at achieving vaccination of the large majority of the overall population. |
| first_indexed | 2024-03-09T12:20:21Z |
| format | Article |
| id | doaj.art-eed488d3b75e48469c2cdc7616553bda |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T12:20:21Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-eed488d3b75e48469c2cdc7616553bda2023-11-30T22:42:39ZengMDPI AGVaccines2076-393X2022-03-0110341710.3390/vaccines10030417Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort StudyFrancesco Paolo Bianchi0Pasquale Stefanizzi1Cinzia Annatea Germinario2Giovanni Migliore3Luigi Vimercati4Andrea Martinelli5Annamaria Lobifaro6Giusy Diella7Angela Maria Vittoria Larocca8Control Room Working GroupSilvio Tafuri9Department of Interdisciplinary Medicine, Aldo Moro University of Bari, 70124 Bari, ItalyDepartment of Interdisciplinary Medicine, Aldo Moro University of Bari, 70124 Bari, ItalyDepartment of Interdisciplinary Medicine, Aldo Moro University of Bari, 70124 Bari, ItalyHospital Direction, Bari Policlinico General Hospital, 70124 Bari, ItalyDepartment of Interdisciplinary Medicine, Aldo Moro University of Bari, 70124 Bari, ItalyDepartment of Interdisciplinary Medicine, Aldo Moro University of Bari, 70124 Bari, ItalyDepartment of Interdisciplinary Medicine, Aldo Moro University of Bari, 70124 Bari, ItalyDepartment of Interdisciplinary Medicine, Aldo Moro University of Bari, 70124 Bari, ItalyHygiene Department, Bari Policlinico General Hospital, 70124 Bari, ItalyDepartment of Interdisciplinary Medicine, Aldo Moro University of Bari, 70124 Bari, ItalyTo deal with the COVID-19 pandemic, a mass vaccination campaign was started in European countries on 27 December 2020. The first vaccine available to immunize healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine. While many studies have shown a high antibody response after the second vaccine dose, antibody persistence over the medium-to-long term has yet to be evaluated. The medium-to-long-term persistence of anti-SARS-CoV-2 antibodies was determined in a sample of fully vaccinated HCWs at Bari Policlinico General Hospital, Italy. This is a observational cohort study. HCWs who completed the immunization basal cycle were screened for anti-SARS-CoV-2 IgG on days 15, 30, 60, 90, and 120 after the second vaccine dose. At each time point, >99% of the screened HCWs were seroprotected. While the geometric mean titer initially declined over time, by 60 days the titer had stabilized. Older subjects seem to lose IgG faster than younger ones. The immunogenicity conferred by the vaccine provides further evidence that it is an essential weapon in efforts to bring the COVID-19 pandemic under control. Accordingly, strict measures should be implemented, ranging from the mandatory vaccination of HCWs to strong incentives aimed at achieving vaccination of the large majority of the overall population.https://www.mdpi.com/2076-393X/10/3/417COVID-19vaccine effectivenessantibodiesdocumented infectionhealthcare workers |
| spellingShingle | Francesco Paolo Bianchi Pasquale Stefanizzi Cinzia Annatea Germinario Giovanni Migliore Luigi Vimercati Andrea Martinelli Annamaria Lobifaro Giusy Diella Angela Maria Vittoria Larocca Control Room Working Group Silvio Tafuri Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study Vaccines COVID-19 vaccine effectiveness antibodies documented infection healthcare workers |
| title | Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study |
| title_full | Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study |
| title_fullStr | Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study |
| title_full_unstemmed | Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study |
| title_short | Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study |
| title_sort | medium to long term immunogenicity of bnt162b2 mrna covid 19 vaccine a retrospective cohort study |
| topic | COVID-19 vaccine effectiveness antibodies documented infection healthcare workers |
| url | https://www.mdpi.com/2076-393X/10/3/417 |
| work_keys_str_mv | AT francescopaolobianchi mediumtolongtermimmunogenicityofbnt162b2mrnacovid19vaccinearetrospectivecohortstudy AT pasqualestefanizzi mediumtolongtermimmunogenicityofbnt162b2mrnacovid19vaccinearetrospectivecohortstudy AT cinziaannateagerminario mediumtolongtermimmunogenicityofbnt162b2mrnacovid19vaccinearetrospectivecohortstudy AT giovannimigliore mediumtolongtermimmunogenicityofbnt162b2mrnacovid19vaccinearetrospectivecohortstudy AT luigivimercati mediumtolongtermimmunogenicityofbnt162b2mrnacovid19vaccinearetrospectivecohortstudy AT andreamartinelli mediumtolongtermimmunogenicityofbnt162b2mrnacovid19vaccinearetrospectivecohortstudy AT annamarialobifaro mediumtolongtermimmunogenicityofbnt162b2mrnacovid19vaccinearetrospectivecohortstudy AT giusydiella mediumtolongtermimmunogenicityofbnt162b2mrnacovid19vaccinearetrospectivecohortstudy AT angelamariavittorialarocca mediumtolongtermimmunogenicityofbnt162b2mrnacovid19vaccinearetrospectivecohortstudy AT controlroomworkinggroup mediumtolongtermimmunogenicityofbnt162b2mrnacovid19vaccinearetrospectivecohortstudy AT silviotafuri mediumtolongtermimmunogenicityofbnt162b2mrnacovid19vaccinearetrospectivecohortstudy |